POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer
Preprint
Abstract
Pancreatic cancer (PC) is broadly resistant to immune checkpoint blockade, although a subset of homologous recombination-deficient (HRD) tumors exhibits durable immune engagement. The genomic features that distinguish these immune-responsive tumors from immune-inert HRD tumors remain poorly understood. Here we identify a microhomology-mediated end joining (MMEJ) repair scar, the MMEJ Deletion Footprint (MDF), as a genomic readout of POLQ-associated error-prone repair that enriches for frameshift indels. Across the multi-omic discovery cohort integrating tumor genomics, single-nucleus transcriptomics and spatial immune profiling, MDF-high HRD PC exhibited increased frameshift-indel-derived neoantigens and interferon programs. MDF was further associated with remodeling of the myeloid compartment toward MHC II-high dendritic cell-like antigen-presenting macrophage states and the immune synapse architecture marked by increased spatial interaction between APC-like macrophages and cytotoxic CD8 + T cells. These tissue-level features aligned with a functional trajectory shift of CD8 + T cells, consistent with effective anti-tumor immunity and was associated with favorable clinical outcomes of patients. Together, our findings position MMEJ-linked repair scarring as actionable biology that connects an HRD genotype to immune organization and suggests rational immunotherapy combinations that may enhance antigen presentation and myeloid activation to extend durable benefit in HRD-lineage cancers.Keywords
Funding Information
- Society for Immunotherapy of Cancer
This publication has 52 references indexed in Scilit:
- Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancerCancer Cell, 2025
- Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas CancerJAMA Oncology, 2024
- Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline VariantsJAMA Oncology, 2022
- Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancerCancer Immunology, Immunotherapy, 2022
- Pancreatic CancerJAMA, 2021
- Challenges and Opportunities for Pancreatic Cancer ImmunotherapyCancer Cell, 2020
- Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive FrontCell, 2020
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal AdenocarcinomaJAMA Oncology, 2019
- A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam ImagingCell, 2018
- DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous TranscriptsCell, 2015